DDInter640 DDInter1376
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unre
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Encorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifaximin
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Encorafenib {u} may lead to a major life threatening interaction when taken with {v} Grepafloxacin
Encorafenib {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Encorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifaximin
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Encorafenib may lead to a major life threatening interaction when taken with Grepafloxacin
Encorafenib may lead to a major life threatening interaction when taken with Lorlatinib